MAP
RVNC

Moody Aldrich Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Moody Aldrich Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-114,173
Closed -$2.11M – 180
2022
Q4 		$2.11M Buy
114,173
+34,189
+43% +$782K 0.43% 81
2022
Q3 		$2.16M Buy
+79,984
New +$1.62M 0.44% 77

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Moody Aldrich Partners's RVNC Position: Q1 2023 in Review

Moody Aldrich Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2023, closing a stake of 114,173 shares — an estimated $2.11M sold.

Moody Aldrich Partners first reported a position in RVNC in Q3 2022 and held it in 2 quarters. The position peaked at $2.16M in Q3 2022. 216 funds tracked by Wall St. Rank hold RVNC as of Q1 2023.

  • Moody Aldrich Partners reported no remaining Revance Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • Moody Aldrich Partners sold 114,173 Revance Therapeutics, Inc. shares in Q1 2023, an estimated $2.11M.
  • Moody Aldrich Partners first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 2 quarters.
  • Moody Aldrich Partners's Revance Therapeutics, Inc. position peaked at $2.16M in Q3 2022.
  • 216 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2023.

Based on Moody Aldrich Partners's 13F filing for Q1 2023, filed 27 Apr 2023.